Postdoctoral position available

mullen at utmdacc.mda.uth.tmc.edu mullen at utmdacc.mda.uth.tmc.edu
Wed Jun 12 14:11:00 EST 1996


Postdoctoral Position in Cancer Immunology Available

A funded position for a postdoctoral investigator is available 
immediately.  The focus of the lab's work is the induction of 
antigen specific cytolytic T cells for the treatment of 
minimal residual metastatic cancer.  Two projects are underway.  
The first involves the quantification of CTL responses to tumor 
associated antigens induced in vivo by chemoablation of poorly 
immunogenic tumors genetically engineered to express metabolic 
suicide genes.  The additional contribution of cytokine expression 
in the tumor microenvironment is also studied.  The second project 
studies graft versus tumor effects in allogeneic bone marrow 
transplantation.  Specifically the impact of active immunization 
of donors with genetically engineered recipient tumor cells on 
generation of antitumor T cells will be assessed, as well as 
the changes in graft versus host disease activity.

Candidates for this position should have some background in immunology, 
hematology and molecular biology.  Techniques used in the lab include: 
development and use of retroviral vectors, subcloning of plasmids, 
tissue culture, cellular T cell assays, tumor transplantation, 
and bone marrow transplantation.  In vivo experiments in inbred 
mice play an important role in the projects.

This position is immediately available.  Salary will depend on 
qualifications.  Please send curriculum vitae and the names and 
telephone numbers of three references to:

Craig A. Mullen, M.D., Ph.D.
Depts. of Experimental Pediatrics & Immunology
U.T. M.D. Anderson Cancer Center
Room B7.4518, Box 88
1515 Holcombe Blvd.
Tel: 713-792-3314
Fax: 713-794-4373
email: mullen at utmdacc.mda.uth.tmc.edu

Representative publications:

Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the 
cytosine deaminase suicide gene can be eliminated in vivo with 
5-fluorocytosine and induce protective immunity to wild type tumor. 
Cancer Res, 54:1503-1506, 1994. 

Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, 
Giovarelli M, Forni G. 5-fluorocytosine induced eradication of 
murine adenocarcinomas engineered to express the cytosine deaminase 
suicide gene requires host immune competence and leaves an efficient 
memory. J. Immunol., 154:5302-5312, 1995.

Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic 
pulmonary metastases with recombinant autologous tumor vaccine 
expressing IL-6 and E. coli cytosine deaminase suicide genes. 
Cancer Research, 56:1361-1366, 1996.

  




More information about the Immuno mailing list